BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

Translate Bio and Sanofi’s bid to develop a COVID-19 mRNA vaccine highlights how manufacturing capacity is among the most visible differentiating factors at this stage in the pandemic counter-response. The partners’ program is one of...
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

After nearly grinding to a halt in the first two months of 2020, venture money has begun to flow to China’s biotechs as investors adjust to investing amid the COVID-19 outbreak. A spate of venture...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

Although Bio-Thera priced its Shanghai IPO Monday, the Guangzhou-based antibody company will likely prove to be the exception among biotechs planning to debut on the Shanghai and Hong Kong exchanges as Asian markets remain volatile...
BioCentury | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
BioCentury | May 30, 2019
Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
BioCentury | Apr 13, 2019
Tools & Techniques

ctDNA inches toward new applications

After establishing itself as a key tool for tumor profiling and patient stratification, circulating tumor DNA is now beginning to make the move into monitoring response to therapy, where it promises an early read of...
BioCentury | Oct 5, 2018
Financial News

Guardant gets pop after IPO; Kodiak prices below range

Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) and ophthalmic company Kodiak Sciences Inc. (NASDAQ:KOD) each priced IPOs late Oct. 3. Guardant priced above its proposed range and posted a big gain on Thursday, while Kodiak...
BioCentury | Oct 4, 2018
Financial News

Guardant gets pop after IPO; Kodiak prices below range

Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) and ophthalmic company Kodiak Sciences Inc. (NASDAQ:KOD) each priced IPOs late Wednesday. Guardant priced above its proposed range and posted a big gain on Thursday, while Kodiak priced...
BioCentury | Sep 13, 2018
Financial News

Guardant files for NASDAQ IPO

Guardant Health Inc. (Redwood City, Calif.) filed on Sept. 6 to raise up to $100 million in an IPO on NASDAQ underwritten by J.P. Morgan, BofA Merrill Lynch, Cowen, Leerink and William Blair. The liquid...
Items per page:
1 - 10 of 52